Iron Deficiency Treatment: Drug Interactions to Know

This reference on iron deficiency drug interactions covers which ones are actually documented, the shared mechanism behind them, why this matters given India's anaemia burden specifically, and what it means for hospital dispensing practice.

Which drugs interact with oral iron supplements?

A pharmacology review identified tetracyclines, the fluoroquinolone ciprofloxacin, the chelating agent penicillamine, the antihypertensive methyldopa, the antiparkinsonian combination levodopa-carbidopa, and thyroxine as drugs with documented interactions with oral iron. The review's authors noted that, even decades after these interactions were first characterised, little is known about concurrent therapy for several of these pairs.

That gap means clinical caution should extend beyond only the best-studied interactions on this list.

Separately, iron is documented to reduce absorption of oral calcium salts when taken together, and heartburn medications, including proton pump inhibitors, are noted to reduce the body's iron absorption in the other direction, an interaction that runs opposite to the chelation mechanism affecting most of the other drugs on this list.

What is the shared mechanism behind these interactions?

The dominant mechanism across nearly all of these interactions is chelation. Iron forms a bound complex with the other drug molecule in the gut, and neither iron nor the co-administered drug absorbs as effectively alone. This is a physical binding process, not a metabolic one, which is why spacing the two doses apart, not adjusting either dose, is the standard fix in the literature.

Levothyroxine is a specific and clinically important example: iron in any form can bind with levothyroxine and meaningfully reduce its absorption, which is why guidance consistently recommends separating the two by several hours rather than co-administering them. The same spacing logic applies to tetracyclines and fluoroquinolones, where reduced absorption can affect both the antibiotic's efficacy and the patient's iron repletion.

Why does this matter more in India specifically?

India's anaemia burden is large enough that these interactions affect prescribing at real scale rather than as an edge case. Comparing National Family Health Survey rounds NFHS-4 and NFHS-5 shows little improvement across age groups: anaemia in pregnant women moved from 50.4% to 52.2%, in children from 58.6% to 67.1%, and in women overall from 53.1% to 57%, despite five decades of government anaemia-control programmes.

Iron deficiency is estimated to account for around 50% of anaemia cases among school-age children and women of reproductive age, and roughly 80% in children aged 2–5, in low- and middle-income settings including India. Given that scale, patients on iron therapy through the government's Anaemia Mukt Bharat programme or private prescription are also very likely to be on other routine medications, thyroxine and calcium supplementation among the most common, making these interactions a routine dispensing consideration rather than a rare one.

What does the Anaemia Mukt Bharat programme mean for iron dispensing at scale?

Anaemia Mukt Bharat, launched in 2018 under the Strengthened National Iron Plus Initiative, targets six population groups with routine iron and folic acid supplementation, aiming to cut anaemia prevalence by one to three percentage points a year. ICMR has separately reviewed the programme's targeting, diagnostics and prophylaxis strategy given the limited progress NFHS data shows.

A programme operating at this population scale means iron-drug interaction awareness needs to be built into routine dispensing counselling, not treated as a specialist pharmacology footnote, since a meaningful share of patients receiving iron supplementation nationally will also be on a co-administered interacting drug at some point in their treatment course.

What should a hospital pharmacy do about these interactions in practice?

A hospital pharmacy dispensing both iron supplements and any interacting drug class, thyroxine and calcium especially, should have a standard dose-spacing counselling step built into its dispensing workflow rather than relying on the prescriber to remember it each time. Thyroid disorders and calcium supplementation are both common alongside anaemia treatment in Indian practice, making this a frequent co-prescription scenario, not a rare one.

When a hospital's own pharmacy dispenses iron and an interacting medication without that counselling step, or when a patient fills the two prescriptions at different, uncoordinated outside chemists, the spacing guidance can easily get lost, undermining both drugs' effectiveness without either patient or prescriber realising it. A managed or in-house pharmacy that dispenses a patient's full medication list together, with pharmacist-level interaction checking built in, catches this in a way that fragmented external dispensing does not. Medyzen's guides on managed hospital pharmacy services, prescription leakage and hospital revenue loss, and hospital pharmacy management challenges cover why keeping a patient's full prescription inside one hospital pharmacy supports safer dispensing as well as continuity of care.

Sources

1. 1Iron supplements: a common cause of drug interactions — PMC, National Institutes of Health
2. 2Levothyroxine Interactions with Food and Dietary Supplements: A Systematic Review — PMC, National Institutes of Health
3. 3Coverage of iron and folic acid supplementation in India: progress under the Anemia Mukt Bharat strategy 2017–20 — PMC, National Institutes of Health
4. 4Prevalence of anemia in India: a systematic review, meta-analysis and geospatial analysis — BMC Public Health
5. 5Ministry of Health & Family Welfare — Anemia Mukt Bharat — Ministry of Health & Family Welfare, Government of India

This article is for informational purposes and is not a substitute for professional medical advice. Dosing schedules and drug combinations should be reviewed by a treating physician or pharmacist for each individual patient.